Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

BEIJING, February 19, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibo

Related Keywords

Shanghai , China , United States , San Francisco , California , Beijing , Haimen Jiangsu , Yuelei Shen , Gilead Sciences Inc , Biocytogen Fully Human Antibody Library , Biocytogen Pharmaceuticals Beijing Co Ltd , Biocytogen Pharmaceuticals , Gilead Sciences , Drug Development , Wilead , Extensive Library , Therapeutic Targets , Human Antibody , Nc ,